These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 24345753)

  • 1. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.
    Desmond R; Townsley DM; Dumitriu B; Olnes MJ; Scheinberg P; Bevans M; Parikh AR; Broder K; Calvo KR; Wu CO; Young NS; Dunbar CE
    Blood; 2014 Mar; 123(12):1818-25. PubMed ID: 24345753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
    Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
    N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
    Olnes MJ; Scheinberg P; Calvo KR; Desmond R; Tang Y; Dumitriu B; Parikh AR; Soto S; Biancotto A; Feng X; Lozier J; Wu CO; Young NS; Dunbar CE
    N Engl J Med; 2012 Jul; 367(1):11-9. PubMed ID: 22762314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.
    Yamazaki H; Ohta K; Iida H; Imada K; Obara N; Tokumine Y; Tomiyama Y; Usuki K; Imajo K; Miyamura K; Sasaki O; Fanghong Z; Hattori T; Tajima T; Matsuda A; Nakao S
    Int J Hematol; 2019 Aug; 110(2):187-196. PubMed ID: 31183813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag: a review of its use in patients with severe aplastic anaemia.
    McCormack PL
    Drugs; 2015 Apr; 75(5):525-31. PubMed ID: 25700916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag, oral immunosuppressant and androgen combination therapy in twelve patients with refractory severe aplastic anemia.
    Gao Q; Zhang L; Zhao X; Zhu Y; Peng G; Li Y; Li Y; Li J; Song L; Ye L; Fan H; Zhou K; Yang W; Yang Y; Jing L; Zhang F
    Hematology; 2020 Dec; 25(1):341-347. PubMed ID: 32915111
    [No Abstract]   [Full Text] [Related]  

  • 7. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
    Peffault de Latour R; Kulasekararaj A; Iacobelli S; Terwel SR; Cook R; Griffin M; Halkes CJM; Recher C; Barraco F; Forcade E; Vallejo JC; Drexler B; Mear JB; Smith AE; Angelucci E; Raymakers RAP; de Groot MR; Daguindau E; Nur E; Barcellini W; Russell NH; Terriou L; Iori AP; La Rocca U; Sureda A; Sánchez-Ortega I; Xicoy B; Jarque I; Cavenagh J; Sicre de Fontbrune F; Marotta S; Munir T; Tjon JML; Tavitian S; Praire A; Clement L; Rabian F; Marano L; Hill A; Palmisani E; Muus P; Cacace F; Frieri C; van Lint MT; Passweg JR; Marsh JCW; Socié G; Mufti GJ; Dufour C; Risitano AM;
    N Engl J Med; 2022 Jan; 386(1):11-23. PubMed ID: 34986284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis.
    Hong Y; Li X; Wan B; Li N; Chen Y
    Clin Drug Investig; 2019 Feb; 39(2):141-156. PubMed ID: 30406906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
    Fattizzo B; Levati G; Cassin R; Barcellini W
    Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecule of the month. Eltrombopag.
    Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592
    [No Abstract]   [Full Text] [Related]  

  • 11. Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.
    Hwang YY; Gill H; Chan TSY; Leung GMK; Cheung CYM; Kwong YL
    Hematology; 2018 Aug; 23(7):399-404. PubMed ID: 29303047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avatrombopag as alternative therapy for severe aplastic anemia patients who are intolerant or unresponsive to eltrombopag.
    Zhang T; Yu Q; Chen X; Yang H; Gong Y; Zhang Y; Liu X; Yang Z; Fang Y; Yan X; Zhou X; Shi J; He G
    Front Immunol; 2024; 15():1393829. PubMed ID: 39114665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia.
    Cheng H; Wang X; Zhou D; Cao J; Larochelle A; Xu KL
    Ann Hematol; 2019 Aug; 98(8):2009-2011. PubMed ID: 30891613
    [No Abstract]   [Full Text] [Related]  

  • 14. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.
    Lengline E; Drenou B; Peterlin P; Tournilhac O; Abraham J; Berceanu A; Dupriez B; Guillerm G; Raffoux E; de Fontbrune FS; Ades L; Balsat M; Chaoui D; Coppo P; Corm S; Leblanc T; Maillard N; Terriou L; Socié G; de Latour RP
    Haematologica; 2018 Feb; 103(2):212-220. PubMed ID: 29170252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.
    Fattizzo B; Kulasekararaj AG; Hill A; Benson-Quarm N; Griffin M; Munir T; Arnold L; Riley K; Ireland R; De Lavallade H; Potter V; Consonni D; Hillmen P; Mufti GJ; Barcellini W; Marsh JCW
    Haematologica; 2019 Nov; 104(11):e494-e496. PubMed ID: 30890599
    [No Abstract]   [Full Text] [Related]  

  • 16. [Safety and efficacy of the use of eltrombopag in a case of severe acquired bone marrow aplasia].
    Rubio-San-Simón A; Lázaro Rodríguez I; Vázquez Gómez F; Vivanco Martínez JL; Pérez Alonso V
    An Pediatr (Engl Ed); 2019 Apr; 90(4):246-247. PubMed ID: 29798814
    [No Abstract]   [Full Text] [Related]  

  • 17. Upfront eltrombopag monotherapy induces stable hematologic remission in pediatric patients with nonsevere idiopathic aplastic anemia.
    Geng W; Kearney S; Nelson S
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27290. PubMed ID: 29932285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
    Assi R; Garcia-Manero G; Ravandi F; Borthakur G; Daver NG; Jabbour E; Burger J; Estrov Z; Dinardo CD; Alvarado Y; Hendrickson S; Ferrajoli A; Wierda W; Cortes J; Kantarjian H; Kadia TM
    Cancer; 2018 Nov; 124(21):4192-4201. PubMed ID: 30307606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia.
    Filippidou M; Avgerinou G; Tsipou H; Tourkantoni N; Katsibardi K; Vlachou A; Roka K; Solomou E; Kattamis A
    Br J Haematol; 2020 Aug; 190(3):e157-e159. PubMed ID: 32529633
    [No Abstract]   [Full Text] [Related]  

  • 20. Eltrombopag in aplastic anemia.
    Desmond R; Townsley DM; Dunbar C; Young NS
    Semin Hematol; 2015 Jan; 52(1):31-7. PubMed ID: 25578417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.